Invivyd to launch antibody trial for long COVID, vaccine‑linked conditions; shares fall

Invivyd

20/01/2026 12:59

** Shares of drugmaker Invivyd IVVD.O fall 2% to $2.41 premarket

** Co says it will start a mid-2026 trial on a new antibody drug VYD2311 for long COVID and reported post-vaccine conditions

** Long COVID refers to persistent symptoms after infection, while vaccine-linked issues may relate to lingering spike protein, per co

**  Co says double-blind study will test whether regular doses of VYD2311 improve symptoms versus placebo

** Co's VYD2311 is similar to Invivyd's authorized antibody pemivibart, used to prevent COVID-19 in people with weak immune systems - IVVD

** Researchers will track physical performance and patient-reported symptoms over several months, co says

** As of last close, stock up ~457% over the past year

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))